# Mechanisms of immunomodulation in lung injury by mesenchymal stromal cell exosomes

> **NIH NIH K99** · BOSTON CHILDREN'S HOSPITAL · 2020 · $107,950

## Abstract

Summary
With no single effective therapy for either the prevention or treatment of bronchopulmonary dysplasia (BPD), a
chronic lung disease of preterm infants, the need for new tools to treat and reduce risk of further complication is
urgent. Mesenchymal stem/stromal cell (MSC) therapy has shown promise in preclinical models of BPD,
demonstrating both histological and functional benefits. We have shown that the therapeutic capacity of MSCs
is comprised in their secretome, and that the major therapeutic vector therein is represented by the exosomes.
Exosomes are submicron vesicles that harbor a diverse array of bioactive cargo (e.g. lipids, diverse proteins,
and small non-coding RNAs). Recently, using a murine model of hyperoxia-induced BPD, we demonstrated that
a bolus dose of human MSC-exosomes (termed MEx), significantly improved lung morphology, pulmonary
development and lung function, decreased lung fibrosis, restored pulmonary blood vessel loss and ameliorated
pulmonary vascular remodeling and pulmonary hypertension. We have also demonstrated that MEx are readily
taken up by macrophages (Mφ) both in vitro and in vivo and, as a result, shift the Mφ phenotype to an anti-
inflammatory, anti-fibrotic, and pro-regulatory state. However, despite the promising therapeutic potential of MEx,
our understanding of their bioactive properties and the molecular mechanism(s) responsible for such effects
remain unclear. Exosomes are a heterogeneous EV population. Exosome subpopulations are known to differ in
biophysical, proteomic and RNA repertoire. Consequently, different MEx subsets mediate alternative biological
functions. In this proposal we predict that only a certain subtype of MEx is responsible for the therapeutic effects,
and that this ‘bioactive’ MEx subset dampens inflammatory signaling in the lung via modulation of Mφ phenotype
and prevents the development of hyperoxia–induced vascular and alveolar injury. To test these hypotheses, we
propose the following specific aims (SA). SA#1: To isolate, characterize and define therapeutic (‘bioactive’) MEx
subsets. SA#2: To assess MEx in vivo biodistribution and anti-inflammatory/immunomodulatory capacity. SA#3:
Investigate how MEx impacts the epigenetic landscape of target cells in our experimental BPD model.
Collectively, this proposal will provide important insights in MEx biology and MEx-target cell interaction, that can
be leveraged to develop effective, novel therapeutic modalities for BPD.

## Key facts

- **NIH application ID:** 9891564
- **Project number:** 1K99HL146986-01A1
- **Recipient organization:** BOSTON CHILDREN'S HOSPITAL
- **Principal Investigator:** Gareth Rhys Willis
- **Activity code:** K99 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $107,950
- **Award type:** 1
- **Project period:** 2020-02-10 → 2020-10-10

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9891564

## Citation

> US National Institutes of Health, RePORTER application 9891564, Mechanisms of immunomodulation in lung injury by mesenchymal stromal cell exosomes (1K99HL146986-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9891564. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*